Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts

Mapel, Douglas W.; Hunt, William C.; Utton, Rose; Baumgartner, Kathy B.; Samet, Jonathan M.; Coultas, David B.; Mapel, D W; Hunt, W C; Utton, R; Baumgartner, K B; Samet, J M; Coultas, D B
June 1998
Thorax;Jun1998, Vol. 53 Issue 6, p469
Academic Journal
journal article
No abstract available.


Related Articles

  • Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan. Haibo Huang; Xiaonu Peng; Nakajima, Jun // BioScience Trends;Aug2013, Vol. 7 Issue 4, p172 

    Idiopathic pulmonary fibrosis is an intractable disease with a median survival time of 2 to 3 years. Serum levels of Krebs von den Lungen-6 (KL-6), surfactant protein A (SP-A), and surfactant protein D (SP-D) are useful biomarkers for idiopathic pulmonary fibrosis and they are widely used in...

  • Interferon Gamma-1b for the Treatment of Idiopathic Pulmonary Fibrosis. du Bois, R.M. // New England Journal of Medicine;10/21/99, Vol. 341 Issue 17, p1302 

    The author discusses the incidence of idiopathic pulmonary fibrosis in Bernalillo County, New Mexico. Data collected from October 1988 through September 1990 in the population-based registry of patients with diffuse lung disease suggests that the prevalence of this disease is roughly 20 cases...

  • Modern Concepts on the Role of Inflammation in Pulmonary Fibrosis. Homer, Robert J.; Elias, Jack A.; Lee, Chun Gun; Herzog, Erica // Archives of Pathology & Laboratory Medicine;Jun2011, Vol. 135 Issue 6, p780 

    Context.-Idiopathic pulmonary fibrosis is a uniformly lethal disease with limited biomarkers and no proven therapeutic intervention short of lung transplantation. Pulmonary fibrosis at one time was thought to be a result of inflammation in the lung. Although some forms of pulmonary fibrosis may...

  • Interferon Gamma-1b Therapy for Advanced Idiopathic Pulmonary Fibrosis. Kalra, Sanjay; Utz, James P.; Ryu, Jay H. // Mayo Clinic Proceedings;Sep2003, Vol. 78 Issue 9, p1082 

    Examines the treatment of advanced idiopathic pulmonary fibrosis/usual interstitial pneumonia with interferon gamma-1b. Duration of treatment; Baseline pulmonary function tests; Patient medical history; Patient survival.

  • Management of the idiopathic interstitial pneumonias. Troy, Lauren; Corte, Tamera Jo // Australian Prescriber;Dec2012, Vol. 35 Issue 6, p202 

    The idiopathic interstitial pneumonias are characterised by varying degrees of lung inflammation and fibrosis. They include primary fibrotic disorders, such as idiopathic pulmonary fibrosis, and primary inflammatory disorders, which may or may not be associated with lung fibrosis. Distinguishing...

  • InterMune Tweaks Design for Confirmatory Esbriet IPF Study. Boggs, Jennifer // BioWorld Today;5/27/2011, Vol. 22 Issue 103, p1 

    The article reports that Brisbane, California-based pharmaceutical company Intermune Inc. in May 2011 announced an upcoming confirmatory trial for idiopathic pulmonary fibrosis drug Esbriet. Intermune senior vice president Bill Bradford says the trial is required to get the U. S. Food and Drug...

  • Trends in long-term survival following acute myocardial infarction and revascularization. Linden, Belinda // British Journal of Cardiac Nursing;Apr2009, Vol. 4 Issue 4, p196 

    A summary of the article "Long Term Survival After Evidence Based Treatment of Acute Myocardial Infarction and Revascularisation: Follow Up of Population Based Perth MONICA Cohort," from the journal "British Medical Journal" is presented. The long-term survival of three cohorts of patients...

  • Combined Pulmonary Fibrosis and Emphysema Alters Physiology but Has Similar Mortality to Pulmonary Fibrosis Without Emphysema. Jankowich, Matthew D.; Rounds, Sharon // Lung;Oct2010, Vol. 188 Issue 5, p365 

    Studies have described individuals with combined pulmonary fibrosis and emphysema (CPFE), with preserved lung volumes, significant reductions in gas exchange, and high prevalence of pulmonary hypertension. While physiologic changes in CPFE are well documented, there is little mortality data in...

  • Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Ying-Wei Lan; Kong-Bung Choo; Chuan-Mu Chen; Tsai-Hsien Hung; Young-Bin Chen; Chung-Hsing Hsieh; Han-Pin Kuo; Kowit-Yu Chong // Stem Cell Research & Therapy;Jul2015, Vol. 6 Issue 1, p1 

    Introduction: Idiopathic pulmonary fibrosis is a progressive diffuse parenchymal lung disorder of unknown etiology. Mesenchymal stem cell (MSC)-based therapy is a novel approach with great therapeutic potential for the treatment of lung diseases. Despite demonstration of MSC grafting, the...

  • Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri. Folcik, Virginia A; Garofalo, Michela; Coleman, Jack; Donegan, James J; Rabbani, Elazar; Suster, Saul; Nuovo, Allison; Magro, Cynthia M; Di Leva, Gianpiero; Nuovo, Gerard J // Modern Pathology;Jun2014, Vol. 27 Issue 6, p851 

    No abstract available.


Read the Article


Sign out of this library

Other Topics